Optogenetic therapy, based on Nobel prize-winning science, involves turning nerve cells on and off using light ...

Record global approvals, CRISPR breakthroughs, and expanding clinical and commercial activity are accelerating demand for cell and gene therapy tools and reagents.Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE ...

Andelyn Biosciences ("Andelyn"), a leading US-based patient-focused cell and gene therapy Contract Development and ...

The US FDA has approved Ultragenyx Pharmaceutical’s rebisufligene etisparvovec (Fayuvi) for paediatric patients with ...

The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma ...

Ultragenyx Pharmaceutical RARE announced that the European Medicines Agency (EMA) has validated its Marketing Authorization ...

The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as ...

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. BOSTON — A medicine increasingly used to ...

September 30, 2026, 10:01 to October 7, 2026, 10:01 (JST)This week, progress was made in preparing for U.S. regulatory ...

Realizing the potential of cell and gene therapies will require organizations to rethink how they finance care and build the ...